<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00969917</url>
  </required_header>
  <id_info>
    <org_study_id>IPI-504-09</org_study_id>
    <nct_id>NCT00969917</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma</brief_title>
  <official_title>A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Infinity Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Infinity Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine the safety profile and overall response
      rate of IPI 504 in patients with advanced dedifferentiated liposarcoma.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Company decision not to start the study
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date>December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety profile and overall response rate (ORR) of IPI 504 in patients with advanced dedifferentiated liposarcoma.</measure>
    <time_frame>Every 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the clinical benefit rate and duration of overall response</measure>
    <time_frame>Every 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Dedifferentiated Liposarcoma</condition>
  <arm_group>
    <arm_group_label>IPI-504</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPI 504 administered twice weekly for 2 weeks followed by 1 week off treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPI-504</intervention_name>
    <description>IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatment</description>
    <arm_group_label>IPI-504</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age at the time of signing informed consent.

          -  Histologic diagnosis of dedifferentiated liposarcoma.

          -  Available archival pathology specimen or tissue sample from a new biopsy for
             confirmation of diagnosis by central pathology reading.

          -  At least one prior chemotherapy regimen for dedifferentiated liposarcoma.

          -  No more than 2 prior chemotherapy regimens for dedifferentiated liposarcoma. Note: Any
             number of non-chemotherapy regimens is permitted.

          -  Measurable disease on computed tomography (CT) or magnetic resonance imaging (MRI) as
             defined by RECIST (version 1.1) with at least one measurable lesion.

          -  Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1.

          -  Life expectancy â‰¥6 months.

        Exclusion Criteria:

          -  Prior treatment with any heat shock protein 90 (Hsp90) inhibitor.

          -  Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable
             disease

          -  Patients with prior hepatic resections or hepatic-directed therapy

          -  Use of a medication or food that is a clinically relevant CYP3A inhibitor or inducer
             within 2 weeks prior to dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2009</study_first_submitted>
  <study_first_submitted_qc>September 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2009</study_first_posted>
  <last_update_submitted>April 13, 2015</last_update_submitted>
  <last_update_submitted_qc>April 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <name_title>Eduardo Rodenas, MD</name_title>
    <organization>Infinity Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

